tgen Archives

TGen study finds origin of lung fungus

Cryptococcus gattii, a virulent fungus that has invaded the Pacific Northwest is highly adaptive and warrants global “public health vigilance,” according to a study by an international team led by the Translational Genomics Research Institute (TGen). C. gattii, which likely originated in Brazil, is responsible for dozens of deaths in recent years since it was… Read More →

TGen teams up with Ceres Nanosciences

The Translational Genomics Research Institute (TGen) and Ceres Nanosciences, Inc. (Ceres) today announced a development collaboration to benefit patients with cancer, infectious diseases, and other life-threatening illnesses. TGen, at the heart of Phoenix’s Biomedical Campus, is recognized as a pioneer in studying genomics, or DNA, to uncover the underlying molecular causes of disease, as well… Read More →

TGen, SHC begin clinical trial for anti-tumor drug

The Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) are studying the safety and effectiveness of a new drug, AG-120, for treatment of patients with solid tumors, especially those with brain tumors and gallbladder bile duct cancer. “AG-120 is designed specifically for those patients who carry the IDH1… Read More →

TGen and NAU celebrate 5-year research pact

Northern Arizona University (NAU) and the Translational Genomics Research Institute (TGen) announced a five-year agreement to promote innovation and quality research benefiting Arizona. The NAU-TGen Memorandum of Understanding (MOU) implements the allocation of state funding as directed by Governor Jan Brewer and the Arizona Legislature, and reaffirms the commitment of both institutions toward quality research,… Read More →

Pancreatic cancer drug successfully tested by TGen

A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer.… Read More →

Gordon named clinical trials medical director

Michael S. Gordon, MD, one of the greater Phoenix area’s leading medical oncologists and cancer researchers, has been named the new Medical Director for the Virginia G. Piper Cancer Center Clinical Trials program at Scottsdale Healthcare. Dr. Gordon will oversee the center’s internationally recognized Phase I clinical trials program, which is known for its leadership… Read More →

Az Business honors healthcare leaders

Each year, Az Business magazine hosts the Healthcare Leadership Awards to honor the women, men and institutions that bring excellence and innovation to Arizona’s healthcare system. Here are the winners and finalists who were chosen by a panel of industry experts and were recognized at the 2014 Healthcare Leadership Awards on Thursday, April 10 at… Read More →

TGen finds clue to stop spread of lung cancer

Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute (TGen). The hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14) are proteins associated with the potential spread of non-small… Read More →

TGen’s Barrett awarded $200,000 research grant

The Pancreatic Cancer Action Network and the American Association for Cancer Research (AACR) awarded a $200,000 grant today to Dr. Michael Barrett of the Translational Genomics Research Institute (TGen). Dr. Barrett, an Associate Professor in TGen’s Clinical Translational Research Division, was one of 14 “outstanding scientists” across the nation named to receive a total of… Read More →

TGen expert honored for cancer research

Dr. Daniel D. Von Hoff, who has been instrumental in developing numerous new cancer treatments, is among this year’s recipients of the Award of Excellence from the Hope Funds for Cancer Research. Dr. Von Hoff, M.D., FACP, who is Physician-In-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), and Chief Scientific Officer for… Read More →

TGen recognized as ‘2014 Economic Driver’

Economic Development , 8 honored

The Greater Phoenix Chamber of Commerce has selected the Translational Genomics Research Institute (TGen) for one of its 2014 Impact Awards. TGen was selected among small to medium business in the category of 2014 Economic Driver. “These companies represent the spirit of the entrepreneur — a spirit that truly makes an impact on our community… Read More →

PCH, Barrow and TGen earn NIH grant

Under a new grant from the National Institutes of Health (NIH), Phoenix Children’s Hospital, Barrow Neurological Institute and the Translational Genomics Research Institute (TGen) are studying the role of extracellular RNA (exRNA) as biomarkers in hemorrhagic brain injuries. The study is being funded by a $4 million grant that is part of an international effort… Read More →

SHC’s Von Hoff honored for cancer advances

In association with its 50th anniversary, the American Society of Clinical Oncology (ASCO) has named Daniel D. Von Hoff, M.D., FACP, one of ASCO’s 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care. Dr. Von Hoff is Chief Scientific Officer for Scottsdale Healthcare’s Virginia G. Piper Cancer Center… Read More →

LaneTerralever Wins Best in Class

Phoenix-based LaneTerralever earned three 2013 Interactive Media Awards (IMA) including a Best in Class award for Thunderbird for Good, and two Outstanding Achievement awards – one for Honeywell Aerospace and the other for Translational Genomics Research Institute (TGen). IMA is a competition designed to elevate the standards of excellence on the Internet, and is presented… Read More →